Author:
Hieken Tina J.,Boughey Judy C.
Publisher
Springer Science and Business Media LLC
Reference5 articles.
1. Ellis MJ, Suman V, Leitch AM, et al. Abstract PD2-10: validation of a predictive model for potential response to neoadjuvant endocrine therapy (NET) in postmenopausal women with clinical stage II or III estrogen receptor positive (ER+) and HER2 negative (HER2−) breast cancer (BC): an ALTERNATE trial analysis (alliance A011106). Cancer Res. 2021;81(Suppl 4):PD2-10.
2. Society of Surgical Oncology. Resource for management options of breast cancer during COVID-19. 2020. https://www.surgonc.org/wp-content/uploads/2020/03/Breast-Resource-during-COVID-19-3.30.20.pdf. Accessed 25 June 2021.
3. Park KU, Gregory M, Bazan J, Lustberg M, Rosenberg S, Blinder V, et al. Neoadjuvant endocrine therapy use in early stage breast cancer during the COVID-19 pandemic. Breast Cancer Res Treatment. 2021. https://doi.org/10.1007/s10549-021-06153-3. Accessed 25 June 2021.
4. Murphy B, Hoskin TL, Degnim AC, Boughey JC, Hieken TJ. Surgical management of the axilla following neoadjuvant endocrine therapy. Ann Surg Oncol. 2021. https://doi.org/10.1245/s10434-021-10385-4.
5. Hieken TJ. The promise of axillary imaging in individualized surgical management of breast cancer patients: another step forward. Ann Surg Oncol. 2014;21:3369–71.